Obviously, this is not an option in humans. “The only thing you can do for human iPSCs is take that cell line and put it into a teratoma assay in a mouse, and ask if the tumor tissues that form ...

But the impact of iPSCs on drug discovery has been frustratingly modest. “Everyone thought that stem cells were going to give us the human cell models that we required to make better drugs ...

Human iPSCs are a new type of pluripotent cell reprogrammed from patient or donor cells into versatile stem cells that can become any cell type. These iPSC-derived cells, which retain disease ...

with human iPSCs playing a crucial role in developing physiologically relevant in vitro models for safer, more effective therapies. They also support patient stratification, improve clinical trial ...

The workflow for editing human iPSCs via CRISPR-Cas9 targeted single-cell cloning can seem daunting. We've broken down the protocol into a quick, easy-to-understand format that will restore your ...

CRISPR’ing human iPSCs allows researchers to manipulate genes to study their functions in the context of specific diseases, or to correct genetic defects in patient cells. One challenge that seamless ...

Racial disparities in mortality are increasing. This article explores how the production of DNA-edited ethnically diverse ...

derivation of functional dopamine neurons from various cell sources including human ES cells, based on the strategy of cell replacement therapy to parkinson’s disease, and ii) specific gene functions ...

It is well known that HLA homozygous iPSCs are often selected to reduce adverse immune response in patients, however, there has recently been an increased demand for type O female blood-derived iPSCs.

Cynata Therapeutics (ASX:CYP) has had its induced pluripotent stem cell (iPSC) derived mesenchymal stem cell (MSCs) verified ...

This dissertation focuses on the glial protein GFAP and Alexander disease, a severe neurological disorder primarily affecting young children. Mutations in the GFAP gene disrupt astrocyte function, ...

Pluristyx has developed a clinical-grade manufacturing process for using a licensed Mad7 gene editing technology to block Human Leukocyte Antigen (HLA) markers expression. Humacyte is optimizing a ...